Peter H O'Donnell

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Topics

Locally Advanced

Clinical Decision Support

Dna Damage Response

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet Asim Bilen, Sandy Srinivas, Earle F Burgess, Chethan Ramamurthy, Saby George, Daniel M Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, Jose Pablo Maroto Rey, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E Rosenberg
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sharyn D Baker, Susan E Bates, Gabriel A Brooks, William L Dahut, Robert B Diasio, Wafik S El-Deiry, William E Evans, William Douglas Figg, Daniel Louis Hertz, J Kevin Hicks, Suneel D Kamath, Pashtoon Murtaza Kasi, Todd C Knepper, Howard L McLeod, Peter H O'Donnell, Mary V Relling, Michelle A Rudek, Tristan M Sissung, D Max Smith, Alex Sparreboom, Sandra M Swain, Christine M Walko
DPYD Testing: Time to Put Patient Safety First. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Deborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, Sumati V Gupta, Ulka N Vaishampayan, Elisabeth I Heath, Philip Garcia, Qianqian Zhao, Menggang Yu, Matthew I Milowsky, Matthew D Galsky
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO precision oncology 7 (2023)
Natalie M Reizine, Peter H O'Donnell
Modern developments in germline pharmacogenomics for oncology prescribing. CA: a cancer journal for clinicians 72 (4) (2022)
Mario E Lacouture, Anisha B Patel, Jonathan E Rosenberg, Peter H O'Donnell
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. The oncologist 27 (3) (2022)
Natalie M Reizine, Keith Danahey, Tien M Truong, David George, Larry K House, Theodore G Karrison, Xander M R van Wijk, Kiang-Teck J Yeo, Mark J Ratain, Peter H O'Donnell
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer 128 (8) (2022)
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Thomas Powles, Elizabeth R Plimack, Dean F Bajorin, Arjun V Balar, Daniel Castellano, Toni K Choueiri, Stephane Culine, Winald R Gerritsen, Howard Gurney, David I Quinn, Jacqueline Vuky, Nicholas J Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros D Grivas
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (10) (2022)
Brittany A Borden, Ellie H Jhun, Keith Danahey, Emily Schierer, Jeffrey L Apfelbaum, Magdalena Anitescu, Randall Knoebel, Sajid Shahul, Tien M Truong, Mark J Ratain, Peter H O'Donnell
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. The pharmacogenomics journal 21 (6) (2021)
Loren Saulsberry, Keith Danahey, Brittany A Borden, Elizabeth Lipschultz, Maimouna Traore, Mark J Ratain, David O Meltzer, Peter H O'Donnell
Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics. NPJ genomic medicine 6 (1) (2021)
Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, Julianne P Hall, Aritro Nath, Dezheng Huo, Gini F Fleming, James N Ingle, Vandana G Abramson, P K Morrow, Anna Maria Storniolo, Andres Forero, Catherine Van Poznak, Minetta C Liu, Jenny C Chang, Douglas E Merkel, Jeffrey M Peppercorn, Hope S Rugo, E Claire Dees, Olwen M Hahn, Philip C Hoffman, Gary L Rosner, R Stephanie Huang, Mark J Ratain, Nancy Cox, Olufunmilayo I Olopade, Antonio C Wolff, M Eileen Dolan, Rita Nanda, null null
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast cancer research and treatment 181 (3) (2020)
Tian Zhang, Michael R Harrison, Peter H O'Donnell, Ajjai S Alva, Noah M Hahn, Leonard J Appleman, Jeremy Cetnar, John M Burke, Mark T Fleming, Matthew I Milowsky, Amir Mortazavi, Neal Shore, Guru P Sonpavde, Emmett V Schmidt, Bojena Bitman, Veerendra Munugalavadla, Raquel Izumi, Priti Patel, Janet Staats, Cliburn Chan, Kent J Weinhold, Daniel J George
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer 126 (20) (2020)
Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, Michael Ong, Alexandra Drakaki, Alexander I Spira, Jingsong Zhang, Michael S Gordon, Arnold N Degboe, Ashok K Gupta, Pralay Mukhopadhyay, Wenmei Huang, Shaad E Abdullah, Natasha Angra, Lorin K Roskos, Xiang Guo, Terence Friedlander
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer 126 (2) (2019)
Rebecca Wellmann, Brittany A Borden, Keith Danahey, Rita Nanda, Blasé N Polite, Walter M Stadler, Mark J Ratain, Peter H O'Donnell
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer 124 (14) (2018)